Manu V. Chakravarthy

5.7k citations

52 papers · 4.1k indexed · h-index 27

Molecular Biology top 5%
Physiology top 1%
Epidemiology top 2%
Endocrinology, Diabetes and Metabolism top 2%
Surgery top 5%

Co-authors: Frank W. Booth Clay F. Semenkovich Espen E. Spangenburg John Turk Trey Coleman Jochen G. Schneider Michael J. Joyner Li Yin
Topics: Liver Disease Diagnosis and Treatment (15 papers)Muscle Physiology and Disorders (9 papers)Diet and metabolism studies (7 papers)
Cited by: Physiology Biochemistry Aging
Journals: Cell Journal of Biological Chemistry Journal of Clinical Investigation
Partner nations: United States United Kingdom Italy

In The Last Decade

Manu V. Chakravarthy

50 papers receiving 4.0k citations

Peers

Countries citing papers authored by Manu V. Chakravarthy

Since Specialization

Citations

This map shows the geographic impact of Manu V. Chakravarthy's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Manu V. Chakravarthy with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Manu V. Chakravarthy more than expected).

Fields of papers citing papers by Manu V. Chakravarthy

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Manu V. Chakravarthy. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Manu V. Chakravarthy. The network helps show where Manu V. Chakravarthy may publish in the future.

Co-authorship network of co-authors of Manu V. Chakravarthy

This figure shows the co-authorship network connecting the top 25 collaborators of Manu V. Chakravarthy. A scholar is included among the top collaborators of Manu V. Chakravarthy based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Manu V. Chakravarthy. Manu V. Chakravarthy is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Efficacy and safety of CT ‐868, a novel, fully biased, dual glucagon‐like peptide‐1/glucose‐dependent insulinotropic polypeptide receptor agonist, in type 2 diabetes: A double‐blind, randomized placebo controlled phase 2 trial 2025 ·Diabetes Obesity and Metabolism ·Manu V. Chakravarthy,Michael Elliott,(unknown),Gabriele E. Sonnenberg,(unknown),(unknown),(unknown),(unknown),José Gerardo González‐González,Stig K. Hansen,Juan P. Frías	1
2	Biased agonism of GLP-1R and GIPR enhances glucose lowering and weight loss, with dual GLP-1R/GIPR biased agonism yielding greater efficacy 2025 ·Cell Reports Medicine ·Rubén Rodríguez,Anne C. Hergarden,(unknown),(unknown),(unknown),(unknown),Teresa Tang,A. R. Patton,Craig R. Lee,Asmita Pant,Daniel A. Erlanson,Johan Enquist,(unknown),(unknown),(unknown),Stig K. Hansen,Jian Luo,Manu V. Chakravarthy	2
3	An open‐label study on ulotaront's effects on insulin‐glucose regulation in schizophrenia patients with metabolic syndrome and prediabetes: Part I 2025 ·Diabetes Obesity and Metabolism ·(unknown),Robert Lew,(unknown),(unknown),Gerald R. Galluppi,Yu‐Luan Chen,Yongquan Lai,Manu V. Chakravarthy,(unknown),Kenneth S. Koblan,Seth C. Hopkins	0
4	Safety, Tolerability, and Biologic Activity of AXA1125 and AXA1957 in Subjects With Nonalcoholic Fatty Liver Disease 2021 ·The American Journal of Gastroenterology ·Stephen A. Harrison,Seth J. Baum,Nadege Gunn,Ziad Younes,Anita Kohli,Rashmee Patil,Margaret James Koziel,(unknown),(unknown),Manu V. Chakravarthy	18
5	Correlations Between MRI Biomarkers PDFF and cT1 With Histopathological Features of Non-Alcoholic Steatohepatitis 2021 ·Frontiers in Endocrinology ·Andrea Dennis,Matt Kelly,Carolina Fernandes,Sofia Mouchti,Jonathan Fallowfield,Gideon M. Hirschfield,Michael Pavlides,Stephen A. Harrison,Manu V. Chakravarthy,Rajarshi Banerjee,Arun J. Sanyal	67
6	The metabolic basis of nonalcoholic steatohepatitis 2020 ·Endocrinology Diabetes & Metabolism ·Manu V. Chakravarthy,Brent A. Neuschwander‐Tetri	68
7	Endogenous Metabolic Modulators: Emerging Therapeutic Potential of Amino Acids 2020 ·iScience ·(unknown),(unknown),Manu V. Chakravarthy,(unknown)	14
8	Effect of CYP3A Inhibition and Induction on the Pharmacokinetics of Suvorexant: Two Phase I, Open-Label, Fixed-Sequence Trials in Healthy Subjects 2019 ·Clinical Drug Investigation ·Rebecca E. Wrishko,Jacqueline B. McCrea,Ka Lai Yee,Wen Liu,Deborah Panebianco,Eric Mangin,Manu V. Chakravarthy,Maria P. Martinez Cantarin,Walter K. Kraft	15
9	Decreased complexity of glucose dynamics preceding the onset of diabetes in mice and rats 2017 ·PLoS ONE ·Xiaohua Douglas Zhang,David Pechter,Liming Yang,(unknown),(unknown),Rumin Zhang,Xiaolan Shen,(unknown),J.H. Connick,Andrea R. Nawrocki,Manu V. Chakravarthy,(unknown)	15
10	Acetyl CoA Carboxylase Inhibition Reduces Hepatic Steatosis but Elevates Plasma Triglycerides in Mice and Humans: A Bedside to Bench Investigation 2017 ·Cell Metabolism ·Chai-Wan Kim,Carol Addy,Jun Kusunoki,Norma N. Anderson,Stanisław Deja,Xiaorong Fu,Shawn C. Burgess,Li Cai,(unknown),Manu V. Chakravarthy,(unknown),Stuart Milstein,Kevin Fitzgerald,David E. Kelley,Jay D. Horton	314
11	Metabolic improvements following Roux-en-Y surgery assessed by solid meal test in subjects with short duration type 2 diabetes 2017 ·BMC Obesity ·Sudha S. Shankar,Lori Mixson,Manu V. Chakravarthy,Robin Chisholm,Anthony J. Acton,RoseMarie Jones,Samer G. Mattar,Deborah L. Miller,(unknown),Chan Beals,S. Aubrey Stoch,David E. Kelley,Robert V. Considine	15
12	Could the mechanisms of bariatric surgery hold the key for novel therapies?: report from a Pennington Scientific Symposium 2011 ·Obesity Reviews ·Charmaine S. Tam,Hans‐Rudolf Berthoud,Marco Bueter,Manu V. Chakravarthy,Allan Geliebter,A. Hajnal,Jens J. Holst,Lee M. Kaplan,Walter J. Pories,Helen E. Raybould,Randy J. Seeley,April D. Strader,Éric Ravussin	37
13	Identification of a Physiologically Relevant Endogenous Ligand for PPARα in Liver 2009 ·Cell ·Manu V. Chakravarthy,Irfan J. Lodhi,Li Yin,(unknown),H. Eric Xu,John Turk,Clay F. Semenkovich	420
14	Inactivation of hypothalamic FAS protects mice from diet-induced obesity and inflammation 2008 ·Journal of Lipid Research ·Manu V. Chakravarthy,Yimin Zhu,Yin Li,Trey Coleman,Kirk L. Pappan,Connie A. Marshall,Michael L. McDaniel,Clay F. Semenkovich	39
15	Respiratory Uncoupling in Skeletal Muscle Delays Death and Diminishes Age-Related Disease 2007 ·Cell Metabolism ·(unknown),Carlos Bernal‐Mizrachi,(unknown),Feng Chu,Jochen G. Schneider,Trey Coleman,James P. Malone,R. Reid Townsend,Manu V. Chakravarthy,Clay F. Semenkovich	94
16	“New” hepatic fat activates PPARα to maintain glucose, lipid, and cholesterol homeostasis 2005 ·Cell Metabolism ·Manu V. Chakravarthy,Zhijun Pan,Yimin Zhu,Karen Tordjman,Jochen G. Schneider,Trey Coleman,John Turk,Clay F. Semenkovich	436
17	p27Kip1: A Key Regulator of Skeletal Muscle Satellite Cell Proliferation 2002 ·Clinical Orthopaedics and Related Research ·Espen E. Spangenburg,Manu V. Chakravarthy,Frank W. Booth	17
18	Exercise and gene expression: physiological regulation of the human genome through physical activity 2002 ·The Journal of Physiology ·Frank W. Booth,Manu V. Chakravarthy,Espen E. Spangenburg	180
19	An Obligation for Primary Care Physicians to Prescribe Physical Activity to Sedentary Patients to Reduce the Risk of Chronic Health Conditions 2002 ·Mayo Clinic Proceedings ·Manu V. Chakravarthy,Michael J. Joyner,Frank W. Booth	133
20	Long-term insulin-like growth factor-I expression in skeletal muscles attenuates the enhanced in vitro proliferation ability of the resident satellite cells in transgenic mice 2001 ·Mechanisms of Ageing and Development ·Manu V. Chakravarthy,Marta L. Fiorotto,Robert J. Schwartz,Frank W. Booth	19

About Manu V. Chakravarthy

Manu V. Chakravarthy is a scholar working on Aging, Physiology and Endocrinology, Diabetes and Metabolism, having authored 52 papers that have together received 4.1k indexed citations. Recurring topics across this work include Liver Disease Diagnosis and Treatment (15 papers), Muscle Physiology and Disorders (9 papers) and Diet and metabolism studies (7 papers). The work is most often cited by research in Physiology (1.6k citations), Biochemistry (368 citations) and Aging (81 citations). Manu V. Chakravarthy has collaborated with scholars based in United States, United Kingdom and Italy. Frequent co-authors include Frank W. Booth, Clay F. Semenkovich, Espen E. Spangenburg, John Turk, Trey Coleman, Jochen G. Schneider, Michael J. Joyner, Frank W. Booth, Li Yin and Yimin Zhu. Their work appears in journals such as Cell, Journal of Biological Chemistry and Journal of Clinical Investigation.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact